Compare Stocks: OCUL, CRNX, LNTH, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$151.72	$156.25	$62.18 ▼ $200.00	$6.08B	-1.22	168,056 shs	171,257 shs
CRNX Crinetics Pharmaceuticals	$84.84	$73.98	$30.25 ▼ $84.89	$9.00B	0.12	2.24 million shs	1.13 million shs
LNTH Lantheus	$100.77	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.16 million shs	1.14 million shs
OCUL Ocular Therapeutix	$10.36	$9.68	$6.23 ▼ $16.44	$2.28B	0.93	2.82 million shs	1.56 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-5.80%	-4.34%	+3.21%	+140.71%
CRNX Crinetics Pharmaceuticals	0.00%	+0.18%	+1.58%	+145.77%	+173.77%
LNTH Lantheus	0.00%	+0.80%	+1.13%	+3.75%	+83.55%
OCUL Ocular Therapeutix	0.00%	-6.50%	+26.81%	+16.01%	-15.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$151.72	$156.25	$62.18 ▼ $200.00	$6.08B	-1.22	168,056 shs	171,257 shs
CRNX Crinetics Pharmaceuticals	$84.84	$73.98	$30.25 ▼ $84.89	$9.00B	0.12	2.24 million shs	1.13 million shs
LNTH Lantheus	$100.77	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.16 million shs	1.14 million shs
OCUL Ocular Therapeutix	$10.36	$9.68	$6.23 ▼ $16.44	$2.28B	0.93	2.82 million shs	1.56 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-5.80%	-4.34%	+3.21%	+140.71%
CRNX Crinetics Pharmaceuticals	0.00%	+0.18%	+1.58%	+145.77%	+173.77%
LNTH Lantheus	0.00%	+0.80%	+1.13%	+3.75%	+83.55%
OCUL Ocular Therapeutix	0.00%	-6.50%	+26.81%	+16.01%	-15.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.63	Moderate Buy	$205.80	35.64% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.53% Downside
LNTH Lantheus	2.29	Hold	$108.11	7.29% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	148.55% Upside

Current Analyst Ratings Breakdown

Latest OCUL, CRNX, LNTH, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/12/2026	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$266.00 ➝ $270.00
8/12/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $214.00
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,168.70	N/A	N/A	$9.71 per share	8.74
LNTH Lantheus	$1.54B	4.27	$6.39 per share	15.78	$16.43 per share	6.13
OCUL Ocular Therapeutix	$51.95M	43.80	N/A	N/A	$3.07 per share	3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	166.73	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.34	18.63	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)

Latest OCUL, CRNX, LNTH, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LNTH Lantheus	0.43	3.06	2.89
OCUL Ocular Therapeutix	0.14	13.10	13.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
LNTH Lantheus	99.06%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
LNTH Lantheus	1.70%
OCUL Ocular Therapeutix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.09 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
OCUL Ocular Therapeutix	230	219.62 million	212.81 million	Optionable

OCUL, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

Man Group plc Takes Position in Ocular Therapeutix, Inc. $OCUL

2 hours ago | marketbeat.com

Bank of America Corp DE Sells 204,268 Shares of Ocular Therapeutix, Inc. $OCUL

4 hours ago | marketbeat.com

224,145 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Deutsche Bank AG

August 28 at 3:37 AM | marketbeat.com

BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL

August 28 at 3:28 AM | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $20,449.66 in Stock

August 27, 2026 | insidertrades.com

Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $20,449.66 in Stock

August 26, 2026 | marketbeat.com

Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 3,035 Shares of Stock

August 26, 2026 | marketbeat.com

Jeffrey Heier Sells 3,296 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

August 26, 2026 | marketbeat.com

Pravin Dugel Sells 21,649 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

August 26, 2026 | marketbeat.com

Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update

August 22, 2026 | finance.yahoo.com

Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress

August 22, 2026 | finance.yahoo.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts

August 22, 2026 | marketbeat.com

Pharmaceuticals stocks Q2 highlights: Ocular Therapeutix (NASDAQ:OCUL)

August 21, 2026 | msn.com

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

August 18, 2026 | seekingalpha.com

Why Is Ocular Therapeutix Stock Gaining Monday?

August 17, 2026 | benzinga.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Should You Buy?

August 17, 2026 | marketbeat.com

Bank of America Securities Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

August 14, 2026 | theglobeandmail.com

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research

August 14, 2026 | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 13, 2026 | globenewswire.com

Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL

August 12, 2026 | marketbeat.com

Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$151.72 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$151.74 +0.03 (+0.02%)

As of 04:00 AM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.84 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$84.97 +0.13 (+0.15%)

As of 07:35 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Lantheus NASDAQ:LNTH

$100.77 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$100.35 -0.42 (-0.42%)

As of 07:48 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$10.36 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$10.40 +0.04 (+0.34%)

As of 07:54 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, CRNX, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, CRNX, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, CRNX, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, CRNX, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools